Wells Fargo Initiates Coverage On Madrigal Pharmaceuticals with Overweight Rating, Announces Price Target of $685

Benzinga Newsdesk www.benzinga.com Neutral 52.9%

Neg 0% Neu 52.9% Pos 0%

Wells Fargo analyst Sadia Rahman initiates coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Overweight rating and announces Price Target of $685.